Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services Are Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:
- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider genetic testing for predisposition to hypertrophic cardiomyopathy (HCM) for individuals who are at risk for development of HCM, defined as having a first-degree relative with established HCM, when there is a known pathogenic gene variant present in that affected relative to be eligible for coverage.**

When Services Are Considered Not Medically Necessary
The use of genetic testing for predisposition to hypertrophic cardiomyopathy (HCM) for individuals with a family history of hypertrophic cardiomyopathy (HCM) in which a first-degree relative with established HCM has tested negative for pathologic variants is considered to be not medically necessary.**

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers genetic testing for predisposition to hypertrophic cardiomyopathy (HCM) for all other patient populations, including but not limited to individuals who have a first-degree relative with clinical HCM, but in whom genetic testing is unavailable to be investigational.*
Policy Guidelines

Due to the complexity of genetic testing for hypertrophic cardiomyopathy and the potential for misinterpretation of results, the decision to test and the interpretation of test results should be performed by, or in consultation with, an expert in the area of medical genetics and/or hypertrophic cardiomyopathy.

To inform and direct genetic testing for at-risk individuals, genetic testing should initially be performed in at least one close relative with definite hypertrophic cardiomyopathy (index case), if possible.

Because there are varying degrees of penetrance for different hypertrophic cardiomyopathy variants, consideration for testing of second- or third-degree relatives may be appropriate in certain circumstances. Some judgment should be allowed for these decisions (e.g., in the case of a small family pedigree). Consultation with an expert in medical genetics and/or the genetics of hypertrophic cardiomyopathy, in conjunction with a detailed pedigree analysis, is appropriate when testing of second- or third-degree relatives is considered.

Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society’s nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

Table PG1. Nomenclature to Report on Variants Found in DNA

<table>
<thead>
<tr>
<th>Previous</th>
<th>Updated</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutation</td>
<td>Disease-associated variant</td>
<td>Disease-associated change in the DNA sequence</td>
</tr>
<tr>
<td>Variant</td>
<td>Change in the DNA sequence</td>
<td></td>
</tr>
<tr>
<td>Familial variant</td>
<td>Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives</td>
<td></td>
</tr>
</tbody>
</table>

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

<table>
<thead>
<tr>
<th>Variant Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathogenic</td>
<td>Disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Likely pathogenic</td>
<td>Likely disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Variant of uncertain</td>
<td>Change in DNA sequence with uncertain effects on disease</td>
</tr>
<tr>
<td>significance</td>
<td></td>
</tr>
<tr>
<td>Likely benign</td>
<td>Likely benign change in the DNA sequence</td>
</tr>
<tr>
<td>Benign</td>
<td>Benign change in the DNA sequence</td>
</tr>
</tbody>
</table>

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology

Genetic Counseling
Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Background/Overview
Familial Hypertrophic Cardiomyopathy

Familial hypertrophic cardiomyopathy is the most common genetic cardiovascular condition, with a phenotypic prevalence of approximately 1 (0.2%) in 500 adults. It is the most common cause of sudden cardiac death in adults younger than 35 years of age and is probably the most common cause of death in young athletes. The overall mortality rate for patients with hypertrophic cardiomyopathy is estimated to be 1% per year in the adult population.

The genetic basis for hypertrophic cardiomyopathy is a defect in the cardiac sarcomere, which is the basic contractile unit of cardiac myocytes and is composed of different protein structures. Around 1400 disease-associated variants in at least 18 different genes have been identified. About 90% of pathogenic variants are missense (ie, 1 amino acid is replaced for another), and the strongest evidence for pathogenicity is available for 11 genes coding for thick filament proteins (MYH7, MYL2, MYL3), thin filament proteins (TNNT2, TNNI3, TNNC1, TPM1, ACTC), intermediate filament proteins (MYBPC3), and the Z-disc adjoining the sarcomere (ACTN2, MYOZ2). Variants in myosin heavy chain (MYH7) and myosin-binding protein C (MYBPC3) are the most common and account for roughly 80% of sarcomeric hypertrophic cardiomyopathy. These genetic defects are inherited in an autosomal dominant pattern with rare exceptions. In patients with clinically documented hypertrophic cardiomyopathy, genetic abnormalities can be identified in approximately 60%. Most patients with clinically documented disease are demonstrated to have a familial pattern, although some exceptions are found presumably due to de novo variants.

Diagnosis and Management

The clinical diagnosis of hypertrophic cardiomyopathy depends on the presence of left ventricular hypertrophy, measured by echocardiography or magnetic resonance imaging (MRI), in the absence of other known causative factors such as valvular disease, long-standing hypertension, or another myocardial disease. In addition to primary cardiac disorders, there are systemic diseases that can lead to left ventricular hypertrophy and thus mimic hypertrophic cardiomyopathy. These include infiltrative diseases such as amyloidosis, glycogen storage diseases (eg, Fabry disease, Pompe
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy #  00270  
Original Effective Date:  04/25/2012  
Current Effective Date:  04/10/2023

disease), and neuromuscular disorders (eg, Noonan syndrome, Friedreich ataxia). These disorders need to be excluded before a diagnosis of familial hypertrophic cardiomyopathy is made.

Hypertrophic cardiomyopathy is a very heterogeneous disorder. Manifestations range from subclinical, asymptomatic disease to severe, life-threatening disease. Wide phenotypic variability exists among individuals, even when an identical variant is present, including among affected family members. This variability in clinical expression may be related to environmental factors and modifier genes. A large percentage of patients with hypertrophic cardiomyopathy, perhaps the majority, are asymptomatic or have minimal symptoms. These patients do not require treatment and are not generally at high-risk for sudden cardiac death. A subset of patients has severe disease that causes a major impact on quality of life and life expectancy. Severe disease can lead to disabling symptoms, as well as complications of hypertrophic cardiomyopathy, including heart failure and malignant ventricular arrhythmias. Symptoms and presentation may include sudden cardiac death due to unpredictable ventricular tachyarrhythmias, heart failure, or atrial fibrillation, or some combination.

Management of patients with hypertrophic cardiomyopathy involves treating cardiac comorbidities, avoiding therapies that may worsen obstructive symptoms, treating obstructive symptoms with β-blockers, calcium channel blockers, and (if symptoms persist) invasive therapy with surgical myectomy or alcohol ablation, optimizing treatment for heart failure, if present, and sudden cardiac death risk stratification. Implantable cardioverter-defibrillator implantation may be indicated if there is a family history of sudden cardiac death.

Diagnostic screening of first-degree relatives and other family members is an important component of hypertrophic cardiomyopathy management. Guidelines have been established for screening clinically unaffected relatives of affected individuals. Screening with physical examination, electrocardiography, and echocardiography is recommended every 12 to 18 months for individuals aged 12 to 18 years and every 3 to 5 years for adults. Additional screening is recommended for any change in symptoms that might indicate the development of hypertrophic cardiomyopathy.

Genetic Testing
Genetic testing has been proposed as a component of screening at-risk individuals to determine predisposition to hypertrophic cardiomyopathy among those patients at-risk. Patients at-risk for hypertrophic cardiomyopathy are defined as individuals who have a close relative with established
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

Hypertrophic cardiomyopathy. Results of genetic testing may influence the management of at-risk individuals, which may, in turn, lead to improved outcomes. Furthermore, results of genetic testing may have implications for decision making in the areas of reproduction, employment, and leisure activities. However, the likelihood of obtaining a positive genetic test in the proband is only about 50% because all genes causing hypertrophic cardiomyopathy have not yet been identified or are absent from testing panels. Failure to identify the causative variant in the proband is an indeterminate result that provides no useful information and precludes predictive testing in 33% to 67% of cases.

Commercial testing has been available since 2003, and numerous companies offer genetic testing for hypertrophic cardiomyopathy. Testing is performed either as a comprehensive or targeted gene test. Comprehensive testing, which is done for an individual without a known genetic variant in the family, analyzes the genes most commonly associated with genetic variants for hypertrophic cardiomyopathy and evaluates whether any potentially pathogenic variants are present. Some available panels include testing for multisystem storage diseases that may include cardiac hypertrophy, such as Fabry disease (GLA), familial transthyretin amyloidosis (TTR), and X-linked Danon disease (LAMP2).

Other panels include testing for genes related to hypertrophic cardiomyopathy and those associated with other cardiac disorders. For example, the Pan Cardiomyopathy panel (Laboratory for Molecular Medicine) is a next-generation sequencing panel of 62 genes associated with hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, catecholaminergic polymorphic ventricular tachycardia, left ventricular noncompaction syndrome, Danon syndrome, Fabry disease, Brugada syndrome, and transthyretin amyloidosis.

For a patient with a known variant in the family, targeted testing is performed. Targeted variant testing evaluates for the presence or absence of a single variant known to exist in a close relative.

It can be difficult to determine the pathogenicity of genetic variants associated with hypertrophic cardiomyopathy. Some studies have reported that assignment of pathogenicity has a relatively high error rate and that classification changes over time. With next-generation sequencing and whole-exome sequencing techniques, the sensitivity of identifying variants on the specified genes has increased substantially. At the same time, the number of variants of uncertain significance is also increased with next-generation sequencing. Also, the percentage of individuals who have more than 1 variant that is thought to be pathogenic is increasing. A 2013 study reported that 9.5% (19/200) of
patients from China with hypertrophic cardiomyopathy had multiple pathogenic variants and that the number of variants correlated with severity of disease.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Sequencing tests for hypertrophic cardiomyopathy are available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. FDA has chosen not to require any regulatory review of this test.

No assay kits have been approved by the FDA for genetic testing for hypertrophic cardiomyopathy.

**Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Familial hypertrophic cardiomyopathy is an inherited condition caused by a disease associated variant in one or more of the cardiac sarcomere genes. Hypertrophic cardiomyopathy is associated with numerous cardiac abnormalities, the most serious of which is sudden cardiac death. Genetic testing for hypertrophic cardiomyopathy associated variants is available through a number of commercial laboratories.

For individuals who are asymptomatic with risk for hypertrophic cardiomyopathy because of a positive family history who receive testing for a specific hypertrophic cardiomyopathy related variant identified in affected family member(s), the evidence includes studies reporting on the clinical validity of testing. Relevant outcomes are overall survival, test accuracy and validity, changes in reproductive decision making, symptoms, and morbid events. For individuals at-risk for hypertrophic cardiomyopathy (first-degree relatives), genetic testing is most useful when there is a
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

known disease-associated variant in the family. In this situation, genetic testing will establish the presence or absence of the same variant in a close relative with a high degree of certainty. Presence of the variant indicates that the relative should undergo a cardiac evaluation upon receiving the variant-positive results. If a hypertrophic cardiomyopathy diagnosis is not made at that time, the patient should be monitored for development of symptoms. Absence of this variant will establish that the individual has not inherited the familial predisposition to hypertrophic cardiomyopathy and thus has a similar risk of developing hypertrophic cardiomyopathy as the general population. Such patients will no longer need ongoing surveillance for the presence of clinical signs of hypertrophic cardiomyopathy. Although no direct evidence comparing outcomes for at-risk individuals managed with and without genetic testing was identified, there is a strong chain of evidence that management changes can improve outcomes with genetic testing when there is a known familial variant. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are asymptomatic with risk for hypertrophic cardiomyopathy because of a positive family history who receive nonspecific testing for a hypertrophic cardiomyopathy-related variant, the evidence includes studies reporting on the clinical validity of testing. Relevant outcomes are overall survival, test accuracy and validity, changes in reproductive decision making, symptoms, and morbid events. Given the wide genetic variation in hypertrophic cardiomyopathy and the likelihood that not all causative variants have been identified, there is imperfect clinical sensitivity. Therefore, a negative test is not sufficient to rule out a disease-associated variant in patients without a known family variant. For at-risk individuals without a known variant in the family, there is no clear relation between testing and improved outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information
Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.
2011 Input
Clinical input was sought to help determine whether the use of genetic testing for predisposition to inherited hypertrophic cardiomyopathy would provide an improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, input was received while this policy was under review in 2011. Input was solicited in January 2011 and provided general agreement with the policy. Additional clinical input in October 2011 was sought to address specific questions. The initial vetting indicated uniform agreement with the medically necessary indication for individuals with a first-degree relative who has a known pathogenic variant. The restriction to first-degree relatives was questioned with mixed responses; 2 reviewers indicated that they agreed with testing only first-degree relatives, 2 reviewers indicated that testing should be offered to non-first-degree relatives, and 1 reviewer was undecided.

The second round of clinical input focused on changes in management that could result from genetic testing. Reviewers were uniform that a positive test would result in heightened surveillance. All but 1 reviewer indicated that a negative test would eliminate the need for future surveillance in all cases. There was general agreement that the surveillance schedule used in clinical practice was that proposed by Maron et al (2003).

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

Heart Failure Society of America
In 2018, the Heart Failure Society of America established practice guidelines on the genetic evaluation of cardiomyopathy via a joint writing group with the American College of Medical Genetics. The expert panel issued the following recommendations related to genetic testing (Table 1).

Table 1. Guidelines on Genetic Testing in Hypertrophic Cardiomyopathy

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>LOE</th>
</tr>
</thead>
</table>

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 9 of 22
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>COR</th>
<th>LOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetic testing is recommended for the most clearly affected family member</td>
<td>A1</td>
<td></td>
</tr>
<tr>
<td>Cascade genetic testing of at-risk family members is recommended for pathogenic and likely pathogenic variants</td>
<td>A1</td>
<td></td>
</tr>
<tr>
<td>In addition to routine newborn screening tests, specialized evaluation of infants with cardiomyopathy is recommended, and genetic testing should be considered</td>
<td>A1</td>
<td></td>
</tr>
</tbody>
</table>

LOE: level of evidence.
Level A evidence indicates genetic evaluation or testing has a high correlation with the cardiomyopathic disease of interest in studies with a moderate or large sample size. Levels of evidence were assigned based on literature review and full consensus of the writing group’s expert opinion.

American College of Cardiology and American Heart Association
In 2020, the American College of Cardiology Foundation and the American Heart Association issued updated joint guidelines on the diagnosis and treatment of hypertrophic cardiomyopathy. Table 2 lists the recommendations on genetic testing.

Table 2. Joint Guidelines on Diagnosis and Treatment of Hypertrophic Cardiomyopathy

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>COR</th>
<th>LOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>In patients with HCM, evaluation of familial inheritance, including a 3-generation family history, is recommended as part of the initial assessment.</td>
<td>1</td>
<td>B-NR</td>
</tr>
<tr>
<td>In patients with HCM, genetic testing is beneficial to elucidate the genetic basis to facilitate the identification of family members at risk for developing HCM (cascade testing).</td>
<td>1</td>
<td>B-NR</td>
</tr>
<tr>
<td>In patients with an atypical presentation of HCM or when another genetic condition is suspected to be the cause, a work-up including genetic testing for HCM and other genetic causes of unexplained cardiac hypertrophy is recommended.</td>
<td>1</td>
<td>B-NR</td>
</tr>
<tr>
<td>In patients with HCM who choose to undergo genetic testing, pre- and posttest genetic counseling by an expert in the genetics of cardiovascular disease is</td>
<td>1</td>
<td>B-NR</td>
</tr>
</tbody>
</table>
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Level</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>When performing genetic testing in an HCM proband, the initial tier of genes tested should include genes with strong evidence to be disease-causing in HCM.</td>
<td>1</td>
<td>B-NR</td>
</tr>
<tr>
<td>In first-degree relatives of patients with HCM, both clinical screening (ECG and 2D echocardiogram) and cascade genetic testing (when a pathogenic/likely pathogenic variant has been identified in the proband) should be offered.</td>
<td>1</td>
<td>B-NR</td>
</tr>
<tr>
<td>In families where a sudden unexplained death has occurred with a postmortem diagnosis of HCM, postmortem genetic testing is beneficial to facilitate cascade genetic testing and clinical screening in first-degree relatives.</td>
<td>1</td>
<td>B-NR</td>
</tr>
<tr>
<td>In patients with HCM who have undergone genetic testing, serial reevaluation of the clinical significance of the variant(s) identified is recommended to assess for variant reclassification, which may impact diagnosis and cascade genetic testing in family members.</td>
<td>1</td>
<td>B-NR</td>
</tr>
<tr>
<td>In affected families with HCM, preconceptation and prenatal reproductive and genetic counseling should be offered.</td>
<td>1</td>
<td>B-NR</td>
</tr>
<tr>
<td>In individuals who are genotype-positive, phenotype-negative for HCM, serial clinical assessment, ECG, and cardiac imaging are recommended at periodic intervals depending on age (every 1 to 2 years in children and adolescents, and every 3 to 5 years in adults) and change in clinical status.</td>
<td>1</td>
<td>B-NR</td>
</tr>
<tr>
<td>In individuals who are genotype-positive, phenotype-negative for HCM, participation in competitive athletics of any intensity is reasonable.</td>
<td>2a</td>
<td>C-LD</td>
</tr>
<tr>
<td>In patients with HCM, the usefulness of genetic testing in the assessment of risk of sudden cardiac death is uncertain.</td>
<td>2b</td>
<td>B-NR</td>
</tr>
<tr>
<td>In patients with HCM who harbor a variant of uncertain significance, the usefulness of clinical genetic testing of phenotype-negative relatives for the purpose of variant reclassification is uncertain.</td>
<td>2b</td>
<td>B-NR</td>
</tr>
</tbody>
</table>
For patients with HCM who have undergone genetic testing and were found to have no pathogenic variants (ie, harbor only benign/likely benign variants), cascade genetic testing of the family is not useful.

Ongoing clinical screening is not indicated in genotype-negative relatives in families with genotype-positive HCM, unless the disease-causing variant is downgraded to variant of uncertain significance, likely benign, or benign variant during follow-up.

In individuals who are genotype-positive, phenotype-negative for HCM, ICD is not recommended for primary prevention.

COR: class of recommendation; ECG: electrocardiogram; HCM: hypertrophic cardiomyopathy; ICD: implantable cardioverter defibrillator; LOE: level of evidence.

In 2015, the American College of Cardiology and American Heart Association issued a joint scientific statement on the eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities. Fifteen task forces were assigned to review the scientific evidence for various cardiovascular diseases and with expert consensus, develop recommendations for athletic participation. Table 3 outlines the recommendations related to hypertrophic cardiomyopathy.

**Table 3. American College of Cardiology/American Heart Association Recommendations for Participation in Sports**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>COR</th>
<th>LOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participation in competitive athletics for asymptomatic, genotype-positive HCM patients without evidence of LV hypertrophy by 2-dimensional echocardiography and CMR is reasonable, particularly in absence of a family history of HCM-related sudden death.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Athletes with a probable or unequivocal clinical expression and diagnosis of HCM (disease phenotype of LV hypertrophy) should not participate in most competitive sports, with the exception of class IA sports (low intensity).</td>
<td>III</td>
<td>C</td>
</tr>
</tbody>
</table>

CMR: cardiovascular magnetic resonance imaging; COR: class of recommendation; HCM: hypertrophic cardiomyopathy; LOE: level of evidence; LV: left ventricular.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Heart Rhythm Society and the European Heart Rhythm Association

In 2011, the Heart Rhythm Society and the European Heart Rhythm Association published joint recommendations on genetic testing for cardiac channelopathies and cardiomyopathies. These recommendations were reaffirmed in 2018 and will be formally reassessed by 2023. For hypertrophic cardiomyopathy (HCM), the following recommendations (both class I) were made:

- “Comprehensive or targeted … HCM genetic testing is recommended for any patient in whom a cardiologist has established a clinical diagnosis of HCM based on examination of the patient’s clinical history, family history, and electrocardiographic/echocardiographic phenotype.”
- “Mutation-specific testing is recommended for family members and appropriate relatives following the identification of the HCM-causative mutation in an index case.”

U.S. Preventive Services Task Force Recommendations

Not applicable

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in Table 4.

Table 4. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04036799</td>
<td>Development of a Risk Calculator to Predict Sudden Cardiac Death With Hypertrophic Cardiomyopathy</td>
<td>572</td>
<td>Dec 2021</td>
</tr>
<tr>
<td>NCT02432092</td>
<td>Pediatric Cardiomyopathy Mutation Analysis</td>
<td>300</td>
<td>Apr 2028</td>
</tr>
</tbody>
</table>
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

<table>
<thead>
<tr>
<th>NCT #</th>
<th>Study Title</th>
<th>Enrollment</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01915615</td>
<td>HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy</td>
<td>2750</td>
<td>Apr 2022</td>
</tr>
<tr>
<td>NCT01736566</td>
<td>The MedSeq Project Pilot Study: Integrating Whole Genome Sequencing Into the Practice of Clinical Medicine</td>
<td>213</td>
<td>Aug 2022</td>
</tr>
<tr>
<td>NCT03846297</td>
<td>Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy</td>
<td>2000</td>
<td>Mar 2027</td>
</tr>
<tr>
<td>Unpublished</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03726424</td>
<td>The Clinical Outcome and Prognosis of Patients With Different Pathogenic Mutations of Hypertrophic Cardiomyopathy</td>
<td>1000</td>
<td>Dec 2019 (unknown)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023


©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy #  00270
Original Effective Date:  04/25/2012
Current Effective Date:  04/10/2023

Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023


42. Maron BJ, Zipes DP, Kovacs RJ. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

Considerations: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. Dec 01 2015; 132(22): e256-61. PMID 26621642


44. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. Aug 2011; 8(8): 1308-39. PMID 21787999

Policy History

<table>
<thead>
<tr>
<th>Original Effective Date: 04/25/2012</th>
<th>Current Effective Date: 04/10/2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/16/2001 Medical Policy Committee review</td>
<td></td>
</tr>
<tr>
<td>08/27/2001 Managed Care Advisory Council approval</td>
<td></td>
</tr>
<tr>
<td>03/21/2002 Medical Policy Committee review. Coverage eligibility changed to reflect current literature.</td>
<td></td>
</tr>
<tr>
<td>03/25/2002 Managed Care Advisory Council approval</td>
<td></td>
</tr>
<tr>
<td>02/03/2004 Medical Director Review</td>
<td></td>
</tr>
<tr>
<td>02/17/2004 Medical Policy Committee review. Format revision. Coverage eligibility change to reflect the investigational status of the technology identified in current literature.</td>
<td></td>
</tr>
<tr>
<td>02/23/2004 Managed Care Advisory Council approval. Claims Processing effective date based on revised policy will be 4/1/04.</td>
<td></td>
</tr>
<tr>
<td>02/01/2006 Medical Director review</td>
<td></td>
</tr>
<tr>
<td>02/15/2006 Medical Policy Committee approval. Format revision, including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged.</td>
<td></td>
</tr>
<tr>
<td>02/23/2006 Quality Care Advisory Council approval</td>
<td></td>
</tr>
<tr>
<td>02/13/2008 Medical Director review</td>
<td></td>
</tr>
<tr>
<td>02/20/2008 Medical Policy Committee approval. No change to coverage eligibility.</td>
<td></td>
</tr>
</tbody>
</table>
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy #  00270
Original Effective Date:  04/25/2012
Current Effective Date:  04/10/2023

02/04/2009  Medical Director review
02/19/2009  Medical Policy Committee approval. No change to coverage eligibility.
02/04/2010  Medical Director review
02/17/2010  Medical Policy Committee approval. Title changed to Extracorporeal Shock Wave Treatment for Plantar Fasciitis and Other Musculoskeletal Conditions.
02/03/2011  Medical Policy Committee review
02/16/2011  Medical Policy Implementation Committee approval. No change to coverage statement.
02/02/2012  Medical Policy Committee review
02/15/2012  Medical Policy Implementation Committee approval. No change to coverage statement.
01/03/2013  Medical Policy Committee review
01/09/2013  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/04/2013  Coding revised
01/09/2014  Medical Policy Committee review
01/15/2014  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/05/2015  Medical Policy Committee review
03/20/2015  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/03/2015  Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
03/03/2016  Medical Policy Committee review
03/16/2016  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017  Coding update: Removing ICD-9 Diagnosis Codes and CPT coding update
03/02/2017  Medical Policy Committee review
03/15/2017  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/01/2018  Medical Policy Committee review
03/21/2018  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/07/2019  Medical Policy Committee review
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

03/20/2019 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/05/2020 Medical Policy Committee review
03/11/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/04/2021 Medical Policy Committee review
03/10/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/03/2022 Medical Policy Committee review
03/09/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/02/2023 Medical Policy Committee review
03/08/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 3/2024

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>81403, 81405, 81406, 81407, 81439, 81479</td>
</tr>
<tr>
<td>HCPCS</td>
<td>S3865, S3866</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment,
Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy

Policy # 00270
Original Effective Date: 04/25/2012
Current Effective Date: 04/10/2023

would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.